Antibody–drug conjugates in hematologic malignancies
Cancer · 01.06.2026 · 132 (S1)
DOI: 10.1002/cncr.70421 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 01.06.2026. Verfasst von Krish Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Hematologic Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) represent an important therapeutic modality for the treatment of various hematologic malignancies. These include gemtuzumab ozogamicin and inotuzumab ozagamicin for acute leukemias; brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine for lymphoid malignancies; and belantamab mafadotin for multiple myeloma. Although ADCs do provide an effective off‐the‐shelf approach to selectively deliver cytotoxic agents by targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen target, linker, or payload that have limited their development. In this review, the clinical development and current role of ADCs in the therapeutic landscape of hematologic malignancies are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarah Cannon Research Institute, Nashville, Tennessee, USA.
ORCID-Profile: Hans C Lee
Zitieren
APA
Patel, K., Strickland, S. A., & Lee, H. C. (2026). Antibody–drug conjugates in hematologic malignancies. Cancer, 132(S1). https://doi.org/10.1002/cncr.70421
Vancouver
Patel K, Strickland SA, Lee HC. Antibody–drug conjugates in hematologic malignancies. Cancer. 2026;132(S1). doi:10.1002/cncr.70421
BibTeX
@article{Patel2026,
author = {Patel, Krish and Strickland, Stephen A and Lee, Hans C},
title = {Antibody–drug conjugates in hematologic malignancies},
journal = {Cancer},
year = {2026},
volume = {132},
number = {S1},
doi = {10.1002/cncr.70421}
}
EUVIMED